Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Cell and Tissue Therapy for the Treatment of Chronic Liver Disease.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Bram, Yaron; Nguyen, Duc-Huy T.; Gupta, Vikas; Park, Jiwoon; Richardson, Chanel; Chandar, Vasuretha; Schwartz, Robert E.
- Source:
Annual Review of Biomedical Engineering; Jun2021, Vol. 23 Issue 1, p517-546, 23p
- Additional Information
- Abstract:
Liver disease is an important clinical problem, impacting 600 million people worldwide. It is the 11th-leading cause of death in the world. Despite constant improvement in treatment and diagnostics, the aging population and accumulated risk factors led to increased morbidity due to nonalcoholic fatty liver disease and steatohepatitis. Liver transplantation, first established in the 1960s, is the second-most-common solid organ transplantation and is the gold standard for the treatment of liver failure. However, less than 10% of the global need for liver transplantation is met at the current rates of transplantation due to the paucity of available organs. Cell- and tissue-based therapies present an alternative to organ transplantation. This review surveys the approaches and tools that have been developed, discusses the distinctive challenges that exist for cell- and tissue-based therapies, and examines the future directions of regenerative therapies for the treatment of liver disease. [ABSTRACT FROM AUTHOR]
- Abstract:
Copyright of Annual Review of Biomedical Engineering is the property of Annual Reviews Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.